Report
Oliver Metzger

Siemens Healthineers : Q4 review -positive finish driven by Varian, outlook implies some downside

>Strong finish with beat on sales and adj. EBIT - Q4 revenues of € 6,056m (+1.0% y-o-y) were 2%/3% ahead of ODDO BHF/consensus estimates. The comparable sales growth was 7.5% (vs 4.3%/4.7% expected) impacted by headwind from the Covid antigen test. Excluding the test, comparable sales growth would have been at a strong 10.8%. The equipment book-to-bill was at a level of 1.16x, following 1.11x at the Q3 results. Adjusted EBIT of € 1,013m (+0.2% y-o-y, margin 16.7%) was...
Underlying
Siemens Healthineers AG

Siemens Healthineers AG is a Germany-based company that supplies technology to the healthcare industry. The Company offers a wide range of products and services in the fields of diagnostic and therapeutic imaging, laboratory and point of care diagnostics, and molecular medicine. It provides medical technology and software solutions, as well as clinical consulting services. Additionally, the Company is developing its digital health and enterprise services trough expanding precision medicine, transforming care delivery, improving patient experience, and digitalizing healthcare to enable healthcare providers to increase value. Siemens AG is a majority shareholder of the Company. The Company is active worldwide.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Oliver Metzger

ResearchPool Subscriptions

Get the most out of your insights

Get in touch